- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00301093
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Vaccination for CML Patients With Persistent Disease on Imatinib Mesylate
RATIONALE: Vaccines made from gene-modified cancer cells may help the body build an effective immune response to kill cancer cells. Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving vaccine therapy together with imatinib mesylate may be an effective treatment for chronic myelogenous leukemia.
PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy when given together with imatinib mesylate in treating patients with chronic phase chronic myelogenous leukemia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Determine the maximum tolerated dose of GM-K562 cell vaccine when administered with imatinib mesylate in patients with persistent chronic phase chronic myelogenous leukemia in first hematologic response.
- Determine the safety and toxic effects of GM-K562 cell vaccination in these patients.
Secondary
- Determine the disease response by serial BCR-ABL quantitative polymerase chain reaction measurements in patients treated with this regimen.
- Determine the development of tumor immunity in patients treated with this regimen.
OUTLINE: This is a dose-escalation study of GM-K562.
Patients continue to receive oral imatinib mesylate at the same stable dose as before study entry. Patients receive GM-K562 subcutaneously on days 1, 8, 15, 29, 43, 57, 85, 113, and 141 in the absence of disease progression or unacceptable toxicity.
Cohorts of 10 patients receive escalating doses of GM-K562 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 10 patients experience dose-limiting toxicity.
After completion of study treatment, patients are followed periodically for 20 years.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana Farber Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Diagnosis of chronic myelogenous leukemia
- Chronic phase disease
- Philadelphia chromosome positive disease
Disease in first complete hematologic response, defined by all of the following:
- Complete normalization of peripheral blood counts with WBC < 10,000/mm^3
- Platelet count < 450,000/mm^3
- No immature cells (e.g., myelocytes, metamyelocytes, or blasts) in the peripheral blood
Persistent molecular evidence of disease
- Detectable BCR-ABL transcript by quantitative polymerase chain reaction
- Less than 2 log reduction in peripheral blood or bone marrow BCR-ABL transcripts levels compared to a standardized baseline
- Must have received imatinib mesylate for > 1 year of which the last 3 months were at stable dose ≥ 300 mg/day
PATIENT CHARACTERISTICS:
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Negative pregnancy test
- No known HIV
- ALT or AST ≤ 3 times upper limit of normal
- Oxygen saturation ≥ 93% at room air
- No history of recent acute myocardial infarction
- No history of unstable angina
- No pulmonary decomposition requiring hospitalization within the past 3 months
- No concurrent and/or uncontrolled psychiatric or medical condition that would preclude study compliance
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No prior allogeneic stem cell transplantation
- At least 2 months since other prior experimental therapy
- At least 6 months since prior participation in another vaccine study
- No concurrent systemic immunosuppressive medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and Toxicity
Time Frame: 3 years
|
To assess the safety and toxicity of GM-K462 vaccination in CP CML patients who have acheived a complete hematologic response to imatinib.
|
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Response
Time Frame: 3 years
|
To assess disease response after GM-K562 vaccination by serial BCR-ABL Q-PCR measurements
|
3 years
|
Tumor immunity
Time Frame: 3 years
|
To characterize the development of tumor immunity in response to vaccination with GM-K562 cells
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Bone Marrow Diseases
- Hematologic Diseases
- Myeloproliferative Disorders
- Leukemia, Myeloid
- Leukemia
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Imatinib Mesylate
Other Study ID Numbers
- 04-126
- P30CA006516 (U.S. NIH Grant/Contract)
- R21CA115043 (U.S. NIH Grant/Contract)
- CDR0000456445 (Registry Identifier: NCI PDQ)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Center for International Blood and Marrow Transplant...National Marrow Donor Program; St. Baldrick's FoundationActive, not recruitingAcute Myelogenous LeukemiaUnited States
-
Massachusetts General HospitalCompleted
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
Clinical Trials on GM-K562 cell vaccine
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Alliance for Cancer Gene TherapyTerminatedMyelodysplastic SyndromesUnited States
-
Dana-Farber Cancer InstituteNational Institutes of Health (NIH); Brigham and Women's HospitalCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome-Refractory Anemia With Excess BlastsUnited States
-
Dana-Farber Cancer InstituteBrigham and Women's HospitalCompletedReduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by VaccinationChronic Lymphocytic LeukemiaUnited States
-
Massachusetts General HospitalDana-Farber Cancer Institute; Brigham and Women's HospitalCompleted
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)Completed
-
Dana-Farber Cancer InstituteActive, not recruitingFollicular LymphomaUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI)Terminated
-
University of PennsylvaniaUniversity of Maryland, College ParkCompletedMultiple MyelomaUnited States
-
CelgeneRecruitingNeoplasmsUnited States, Belgium, Spain, Switzerland, Canada, France, Germany, Japan, Finland, United Kingdom, Austria, Italy, Netherlands, Norway, Sweden
-
San Antonio Military Medical CenterNuGenerex Immuno-Oncology; Norwell, Inc.CompletedBreast CancerUnited States, Germany, Greece